Evaluating drug targets through human loss-of-function genetic variation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Naturally occurring human genetic variants that are predicted to inactivate protein-coding genes provide an in vivo model of human gene inactivation that complements knockout studies in cells and model organisms. Here we report three key findings regarding the assessment of candidate drug targets using human loss-of-function variants. First, even essential genes, in which loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs. Second, in most genes, loss-of-function variants are sufficiently rare that genotype-based ascertainment of homozygous or compound heterozygous ‘knockout’ humans will await sample sizes that are approximately 1,000 times those presently available, unless recruitment focuses on consanguineous individuals. Third, automated variant annotation and filtering are powerful, but manual curation remains crucial for removing artefacts, and is a prerequisite for recall-by-genotype efforts. Our results provide a roadmap for human knockout studies and should guide the interpretation of loss-of-function variants in drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationThe mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Self-citationDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“With the cost of drug discovery driven overwhelmingly by failure 50 , successful interpretation of LoF data to select the right targets and right clinical pathways will yield outsize benefits for research productivity and, ultimately, human health.”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Self-citationThe mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2019) · doi:10.1101/531210 · Cited by 1,662
Self-citationKing, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00885-0 · Cited by 401
Self-citation
Metadata
- Authors
- Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., Genome Aggregation Database Production Team, Alföldi, J., Armean, I. M., Banks, E., Bergelson, L., Cibulskis, K., Collins, R. L., Connolly, K. M., Covarrubias, M., Cummings, B. B., Daly, M. J., Donnelly, S., Farjoun, Y., Ferriera, S., Francioli, L., Gabriel, S., Gauthier, L. D., Gentry, J., Gupta, N., Jeandet, T., Kaplan, D., Karczewski, K. J., Laricchia, K. M., Llanwarne, C., Minikel, E. V., Munshi, R., Neale, B. M., Novod, S., O’Donnell-Luria, A. H., Petrillo, N., Poterba, T., Roazen, D., Ruano-Rubio, V., Saltzman, A., Samocha, K. E., Schleicher, M., Seed, C., Solomonson, M., Soto, J., Tiao, G., Tibbetts, K., Tolonen, C., Vittal, C., Wade, G., Wang, A., Wang, Q., Ware, J. S., Watts, N. A., Weisburd, B., Whiffin, N., Genome Aggregation Database Consortium, Aguilar Salinas, C. A., Ahmad, T., Albert, C. M., Ardissino, D., Atzmon, G., Barnard, J., Beaugerie, L., Benjamin, E. J., Boehnke, M., Bonnycastle, L. L., Bottinger, E. P., Bowden, D. W., Bown, M. J., Chambers, J. C., Chan, J. C., Chasman, D., Cho, J., Chung, M. K., Cohen, B., Correa, A., Dabelea, D., Daly, M. J., Darbar, D., Duggirala, R., Dupuis, J., Ellinor, P. T., Elosua, R., Erdmann, J., Esko, T., Färkkilä, M., Florez, J., Franke, A., Getz, G., Glaser, B., Glatt, S. J., Goldstein, D., Gonzalez, C., Groop, L., Haiman, C., Hanis, C., Harms, M., Hiltunen, M., Holi, M. M., Hultman, C. M., Kallela, M., Kaprio, J., Kathiresan, S., Kim, B.-J., Kim, Y. J., Kirov, G., Kooner, J., Koskinen, S., Krumholz, H. M., Kugathasan, S., Kwak, S. H., Laakso, M., Lehtimäki, T., Loos, R. J. F., Lubitz, S. A., Ma, R. C. W., MacArthur, D. G., Marrugat, J., Mattila, K. M., McCarroll, S., McCarthy, M. I., McGovern, D., McPherson, R., Meigs, J. B., Melander, O., Metspalu, A., Neale, B. M., Nilsson, P. M., O’Donovan, M. C., Ongur, D., Orozco, L., Owen, M. J., Palmer, C. N. A., Palotie, A., Park, K. S., Pato, C., Pulver, A. E., Rahman, N., Remes, A. M., Rioux, J. D., Ripatti, S., Roden, D. M., Saleheen, D., Salomaa, V., Samani, N. J., Scharf, J., Schunkert, H., Shoemaker, M. B., Sklar, P., Soininen, H., Sokol, H., Spector, T., Sullivan, P. F., Suvisaari, J., Tai, E. S., Teo, Y. Y., Tiinamaija, T., Tsuang, M., Dan Turner, T., Tusie-Luna, T., Vartiainen, E., Vawter, M. P., Ware, J. S., Watkins, H., Weersma, R. K., Wessman, M., Wilson, J. G., Xavier, R. J., Schreiber, S. L., & MacArthur, D. G.
- Venue
- Nature
- Published
- 2020-05-27
- Volume
- 581
- Issue
- 7809
- Pages
- 459-464
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3029351535
- Cited by
- 187
- References
- 41
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating drug targets through human loss-of-function genetic variation. https://app.cochat.ai/papers/10.1038/s41586-020-2267-z
- The paper
- Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., Genome Aggregation Database Production Team, Alföldi, J., Armean, I. M., Banks, E., Bergelson, L., Cibulskis, K., Collins, R. L., Connolly, K. M., Covarrubias, M., . . . MacArthur, D. G. (2020). Evaluating drug targets through human loss-of-function genetic variation. Nature. https://doi.org/10.1038/s41586-020-2267-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.